首页> 外文期刊>Drug Design, Development and Therapy >Custom fractional factorial designs to develop atorvastatin self-nanoemulsifying and nanosuspension delivery systems – enhancement of oral bioavailability
【24h】

Custom fractional factorial designs to develop atorvastatin self-nanoemulsifying and nanosuspension delivery systems – enhancement of oral bioavailability

机译:定制分数因子设计以开发阿托伐他汀自纳米乳化和纳米混悬剂输送系统–增强口服生物利用度

获取原文
           

摘要

Abstract: Poor water solubility of a drug is a major challenge in drug delivery research and a main cause for limited bioavailability and pharmacokinetic parameters. This work aims to utilize custom fractional factorial design to assess the development of self-nanoemulsifying drug delivery systems (SNEDDS) and solid nanosuspensions (NS) in order to enhance the oral delivery of atorvastatin (ATR). According to the design, 14 experimental runs of ATR SNEDDS were formulated utilizing the highly ATR solubilizing SNEDDS components: oleic acid, Tween 80, and propylene glycol. In addition, 12 runs of NS were formulated by the antisolvent precipitation–ultrasonication method. Optimized formulations of SNEDDS and solid NS, deduced from the design, were characterized. Optimized SNEDDS formula exhibited mean globule size of 73.5 nm, zeta potential magnitude of -24.1 mV, and 13.5 μs/cm of electrical conductivity. Optimized solid NS formula exhibited mean particle size of 260.3 nm, 7.4 mV of zeta potential, and 93.2% of yield percentage. Transmission electron microscopy showed SNEDDS droplets formula as discrete spheres. The solid NS morphology showed flaky nanoparticles with irregular shapes using scanning electron microscopy. The release behavior of the optimized SNEDDS formula showed 56.78% of cumulative ATR release after 10 minutes. Solid NS formula showed lower rate of release in the first 30 minutes. Bioavailability estimation in Wistar albino rats revealed an augmentation in ATR bioavailability, relative to ATR suspension and the commercial tablets, from optimized ATR SNEDDS and NS formulations by 193.81% and 155.31%, respectively. The findings of this work showed that the optimized nanocarriers enhance the oral delivery and pharmacokinetic profile of ATR.
机译:摘要:药物的水溶性差是药物递送研究中的主要挑战,也是生物利用度和药代动力学参数有限的主要原因。这项工作旨在利用定制的分数阶乘设计来评估自我纳米乳化药物递送系统(SNEDDS)和固体纳米悬浮液(NS)的开发,以增强阿托伐他汀(ATR)的口服递送。根据设计,利用高度可溶解ATR的SNEDDS组分(油酸,吐温80和丙二醇)配制了14个ATR SNEDDS实验样品。此外,通过反溶剂沉淀-超声法配制了12种NS。从设计推导得出了SNEDDS和固体NS的优化配方。优化的SNEDDS公式显示平均球大小为73.5 nm,ζ电势值为-24.1 mV,电导率为13.5μs/ cm。优化的固态NS配方的平均粒径为260.3 nm,ζ电位为7.4 mV,收率的93.2%。透射电子显微镜显示SNEDDS液滴的配方为离散球体。固体NS形态使用扫描电子显微镜显示出具有不规则形状的薄片状纳米颗粒。优化的SNEDDS配方的释放行为显示10分钟后累积ATR释放的56.78%。固态NS配方在前30分钟内显示出较低的释放速率。 Wistar白化病大鼠的生物利用度估算显示,相对于ATR悬浮液和市售片剂,优化的ATR SNEDDS和NS制剂的ATR生物利用度分别增加了193.81%和155.31%。这项工作的发现表明,优化的纳米载体增强了ATR的口服递送和药代动力学特性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号